Abstract
We aimed to investigate the use of free glycosaminoglycan profiles (GAGomes) and cfDNA in plasma to differentiate between lung cancer and benign lung disease. GAGs were analyzed using the MIRAM® Free Glycosaminoglycan Kit with ultra-high-performance liquid chromatography and electrospray ionization triple-quadrupole mass spectrometry. We detected two GAGome features, 0S chondroitin sulfate (CS) and 4S CS, with cancer-specific changes. Based on the observed GAGome changes, we devised a model to predict lung cancer. The model, named the GAGome score, could detect lung cancer with 41.2% sensitivity (95% CI: 9.2-54.2%) at 96.4% specificity (CI: 95.2-100.0%, n=113). Furthermore, we found that the GAGome score, when combined with a cfDNA test, could increase the sensitivity for lung cancer from 42.6% (95% CI: 31.7-60.6%, cfDNA alone) to 70.5% (CI: 57.4 - 81.5%) at 95% specificity (CI: 75.1-100%, n=74). Notably, the combined GAGome and cfDNA testing improved the sensitivity, especially in early stages, relative to the cfDNA alone. Our findings show that plasma GAGome profiles can enhance cfDNA testing performance, highlighting the applicability of a multiomics approach in lung cancer diagnostics.
Competing Interest Statement
F. Gatto and J. Nielsen are shareholders in Elypta AB. F. Gatto and S. Bratulic are employed at Elypta AB. J. Nielsen is a board member at Elypta AB. Elypta AB has a commercial interest in part of the technology described in this study. Remaining authors have no conflicts to declare.
Funding Statement
This work was funded by Nyckelfonden-Orebro University Hospital Research Foundation, Lions fund for cancer research Uppsala-Orebro and Uppsala-Orebro Regional research council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the regional ethics committee board in Uppsala, Sweden (Approval 2015-400, 2021-01478).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
